Cost of coronavirus care may turn some toward telehealth

Telehealth is having a moment in the sun as a possible answer to help mitigate the spread of the coronavirus by limiting exposure risks to patients and healthcare professionals. In addition, the high cost of COVID-19 care means a huge portion of Americans would think twice about reaching out for treatment and testing.

However, more Americans are open to using telemedicine services to talk to a doctor online for treatment and care, according to a survey of more than 1,000 respondents by Healthinsurance.com.

A whopping 61% of respondents said they have avoided seeking medical care because of the cost. Another 39% said they would “think twice” about seeking medical care for coronavirus due to the treatment cost. Yet, about 64% said they would use telemedicine while practicing social distancing.

Only 21% of respondents have used telemedicine, and 9% have used it during the COVID-19 pandemic. Most respondents (61%) said they were familiar with telemedicine before the pandemic. Unfortunately, only 38% of respondents said their doctor offers visits by telephone.

The high cost of treating coronavirus has come under the limelight after one patient received a medical bill topping $34,000 for care related to COVID–19.

About half of respondents––54%––said a combined effort between the government and health insurance companies should pay for testing in the case of an epidemic like COVID-19. Already, many major health insurers have waived testing cost-sharing for members, but few have waived treatment costs related to COVID­–19 care.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.